Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2017
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
31,913
+50.0%
|
$2,074,345
$65.85 P/Share
|
|
Feb 27
2017
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
11,771
+24.59%
|
$765,115
$65.85 P/Share
|
|
Feb 27
2017
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
101,552
+14.47%
|
$6,600,880
$65.85 P/Share
|
|
Feb 27
2017
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,707
+7.93%
|
$240,955
$65.85 P/Share
|
|
Feb 27
2017
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
16,995
+13.76%
|
$1,104,675
$65.85 P/Share
|
|
Feb 27
2017
|
Michael J Holston EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,159
+16.3%
|
$790,335
$65.85 P/Share
|
|
Feb 27
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,797
+16.2%
|
$181,805
$65.85 P/Share
|
|
Feb 27
2017
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
32,670
+24.33%
|
$2,123,550
$65.85 P/Share
|
|
Feb 27
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
39,970
+50.0%
|
$2,598,050
$65.85 P/Share
|
|
Feb 14
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Open market or private sale
|
Direct |
2,954
-20.19%
|
$189,056
$64.73 P/Share
|
|
Feb 08
2017
|
Patricia F Russo Director |
SELL
Open market or private sale
|
Direct |
5,000
-27.55%
|
$320,000
$64.42 P/Share
|
|
Feb 08
2017
|
Patricia F Russo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+21.6%
|
$175,000
$35.19 P/Share
|
|
Feb 07
2017
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
10,125
-1.99%
|
-
|
|
Feb 06
2017
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$320,000
$64.51 P/Share
|
|
Feb 06
2017
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$255,000
$51.86 P/Share
|
|
Feb 03
2017
|
Thomas R Cech Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$315,000
$63.42 P/Share
|
|
Feb 03
2017
|
Thomas R Cech Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$175,000
$35.19 P/Share
|
|
Feb 03
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
36,335
-100.0%
|
$2,289,105
$63.73 P/Share
|
|
Feb 03
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
36,335
+35.96%
|
$1,271,725
$35.03 P/Share
|
|
Feb 03
2017
|
Michael J Holston EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
91,959
-35.32%
|
$5,793,417
$63.84 P/Share
|
|
Feb 03
2017
|
Michael J Holston EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
77,959
+24.31%
|
$4,599,581
$59.04 P/Share
|
|
Feb 03
2017
|
Wendell Peter C Director |
SELL
Open market or private sale
|
Direct |
15,000
-93.75%
|
$945,000
$63.69 P/Share
|
|
Feb 03
2017
|
Wendell Peter C Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.5%
|
$480,000
$32.51 P/Share
|
|
Nov 10
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
133,920
-20.83%
|
$8,704,800
$65.03 P/Share
|
|
Nov 10
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
133,920
+17.24%
|
$3,080,160
$23.45 P/Share
|
|
Nov 09
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
6,080
-1.18%
|
$395,200
$65.0 P/Share
|
|
Nov 09
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
6,080
+1.17%
|
$139,840
$23.45 P/Share
|
|
Nov 07
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
85,523
-68.62%
|
$5,131,380
$60.02 P/Share
|
|
Nov 07
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
85,523
+21.69%
|
$3,420,920
$40.28 P/Share
|
|
Nov 02
2016
|
Wendell Peter C Director |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$295,000
$59.5 P/Share
|
|
Nov 02
2016
|
Wendell Peter C Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$255,000
$51.86 P/Share
|
|
Nov 02
2016
|
Rochelle B Lazarus Director |
SELL
Open market or private sale
|
Direct |
20,000
-81.32%
|
$1,180,000
$59.06 P/Share
|
|
Nov 02
2016
|
Rochelle B Lazarus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.25%
|
$740,000
$37.35 P/Share
|
|
Oct 03
2016
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
40,800
-31.63%
|
$2,529,600
$62.07 P/Share
|
|
Oct 03
2016
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Exercise of conversion of derivative security
|
Direct |
40,800
+24.03%
|
$1,795,200
$44.19 P/Share
|
|
Sep 01
2016
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
39,200
-100.0%
|
$2,430,400
$62.61 P/Share
|
|
Sep 01
2016
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
39,200
+50.0%
|
$1,293,600
$33.49 P/Share
|
|
Aug 10
2016
|
Clark Golestani EVP & Chief Info Officer |
SELL
Open market or private sale
|
Direct |
3,000
-17.56%
|
$189,000
$63.03 P/Share
|
|
Aug 05
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
392,000
-16.46%
|
$23,912,000
$61.95 P/Share
|
|
Aug 05
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
392,000
+19.16%
|
$12,936,000
$33.88 P/Share
|
|
Aug 04
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,000
-28.14%
|
$399,000
$57.8 P/Share
|
|
Aug 02
2016
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Payment of exercise price or tax liability
|
Direct |
1,619
-4.31%
|
$93,902
$58.66 P/Share
|
|
Aug 02
2016
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
5,150
+12.06%
|
-
|
|
Aug 02
2016
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
13,600
-2.6%
|
-
|
|
Jul 05
2016
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
45,000
-18.02%
|
$2,565,000
$57.96 P/Share
|
|
Jul 05
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
27,621
-5.02%
|
$1,602,018
$58.0 P/Share
|
|
Jul 05
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
27,621
+4.78%
|
$1,408,671
$51.02 P/Share
|
|
Jul 01
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
32,379
-5.84%
|
$1,877,982
$58.0 P/Share
|
|
Jul 01
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
32,379
+5.51%
|
$1,651,329
$51.02 P/Share
|
|
Jul 01
2016
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
30,000
-18.5%
|
$1,710,000
$57.49 P/Share
|